Quantbot Technologies LP Buys 92,273 Shares of DexCom, Inc. $DXCM

Quantbot Technologies LP grew its stake in DexCom, Inc. (NASDAQ:DXCM) by 2,255.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 96,364 shares of the medical device company’s stock after acquiring an additional 92,273 shares during the quarter. Quantbot Technologies LP’s holdings in DexCom were worth $6,484,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Andra AP fonden bought a new stake in DexCom during the second quarter valued at about $26,000. Twin Peaks Wealth Advisors LLC purchased a new stake in shares of DexCom during the second quarter valued at about $26,000. SJS Investment Consulting Inc. lifted its position in shares of DexCom by 4,800.0% during the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock valued at $26,000 after buying an additional 384 shares during the last quarter. Financial Consulate Inc. bought a new stake in shares of DexCom in the 3rd quarter valued at about $29,000. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of DexCom in the 2nd quarter worth approximately $45,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Trading Down 1.3%

DexCom stock opened at $73.43 on Friday. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $89.98. The stock has a 50-day moving average price of $70.24 and a 200 day moving average price of $69.15. The company has a market capitalization of $28.26 billion, a price-to-earnings ratio of 34.97, a price-to-earnings-growth ratio of 1.43 and a beta of 1.49.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.03. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The firm had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.25 billion. During the same quarter in the prior year, the business earned $0.45 earnings per share. The business’s quarterly revenue was up 13.1% compared to the same quarter last year. Sell-side analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Citigroup reiterated a “buy” rating and set a $77.00 price objective (up from $75.00) on shares of DexCom in a research note on Thursday, December 11th. Barclays reaffirmed an “underweight” rating and set a $72.00 price target (up from $71.00) on shares of DexCom in a research report on Friday, February 13th. Leerink Partners reiterated an “outperform” rating and set a $92.00 price objective on shares of DexCom in a report on Tuesday, December 16th. UBS Group lowered their price objective on DexCom from $106.00 to $95.00 and set a “buy” rating for the company in a research report on Monday, November 3rd. Finally, Canaccord Genuity Group set a $95.00 target price on DexCom and gave the company a “buy” rating in a research report on Friday, February 13th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $85.18.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.